Jun 18, 2020
Nephrologists Are Hesitant to Fully Embrace Janssen's INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease
Mar 20, 2020
National Kidney Foundation Honors Janssen Pharmaceutical Companies of Johnson & Johnson with 2020 Corporate Innovator Award
Nov 09, 2019
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function
Sep 30, 2019
FDA Approves New Drug to Treat Diabetes-Related Kidney Disease
Jun 11, 2019
Canagliflozin Shown to Improve Cardiovascular and Renal Outcomes in People with Type 2 Diabetes and Kidney Disease
Jun 11, 2019
INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
May 22, 2019
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
Apr 14, 2019
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
Mar 28, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
Oct 30, 2018
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Oct 02, 2018
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
Jul 16, 2018
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
Jul 13, 2018
U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application
Jun 24, 2018
Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Jun 24, 2018
Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 Diabetes
Jun 23, 2018
Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
Jun 12, 2018
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
Jun 08, 2018
New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association's 78th Annual Scientific Sessions
May 29, 2018
Invokana: The Diabetic Drug That Costs a Limb
May 24, 2018
New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY